UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets

Multiple sclerosis, 2018-02, Vol.24 (2), p.222-226

2018

Volltextzugriff (PDF)

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study

Multiple sclerosis, 2019-05, Vol.25 (6), p.819-827

2019

Volltextzugriff (PDF)

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

Journal of clinical oncology, 2010-06, Vol.28 (16), p.2712-2718

2010

Volltextzugriff (PDF)

Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer

Frontiers in oncology, 2022-12, Vol.12, p.981940

2022

Volltextzugriff (PDF)

Placebo influences on dyskinesia in Parkinson's disease

Movement disorders, 2008-04, Vol.23 (5), p.700-707

2008

Volltextzugriff (PDF)

Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis

Clinical pharmacokinetics, 2019-03, Vol.58 (3), p.325-333

2019

Volltextzugriff (PDF)

Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis

Multiple sclerosis and related disorders, 2019-04, Vol.29, p.157-167

2019

Volltextzugriff (PDF)

A phase I study of highly potent oral ATR inhibitor (ATRi) tuvusertib plus oral PARP inhibitor (PARPi) niraparib in patients with solid tumors

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.3018-3018

2024

Volltextzugriff (PDF)

WED 182 Cladribine tablets effects on lymphocytes in ms patients

Journal of neurology, neurosurgery and psychiatry, 2018-10, Vol.89 (10), p.A25-A25

2018

Volltextzugriff (PDF)

Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis

Multiple sclerosis and related disorders, 2019-04, Vol.29, p.168-174

2019

Volltextzugriff (PDF)

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

The lancet oncology, 2014-09, Vol.15 (10), p.1100-1108

2014

Volltextzugriff (PDF)

Long-term Lymphocyte Counts in Patients with RRMS Treated with Cladribine Tablets 3.5 mg/kg: Total Lymphocytes, B-, and T-cell Subsets (P5.364)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study

Neuro-oncology (Charlottesville, Va.), 2015-05, Vol.17 (5), p.708-717

2015

Volltextzugriff (PDF)

First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors

Clinical cancer research, 2024-05, Vol.30 (10), p.2057-2067

2024

Volltextzugriff (PDF)

PO135 Cladribine tablets in rrms: lymphocyte counts

Journal of neurology, neurosurgery and psychiatry, 2017-12, Vol.88 (Suppl 1), p.A48-A48

2017

Volltextzugriff (PDF)

Absolute lymphocyte count recovery in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY Extension (P5.379)

Neurology, 2017-04, Vol.88 (16_supplement)

2017

Volltextzugriff (PDF)

THUR 178 Infections during grade 3/4 lymphopenia with cladribine tablets

Journal of neurology, neurosurgery and psychiatry, 2018-10, Vol.89 (10), p.A23-A24

2018

Volltextzugriff (PDF)

Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial

Movement disorders, 2007-01, Vol.22 (2), p.179-186

2007

Volltextzugriff (PDF)

Integrated Safety Analysis of Infections during Periods of Grade 3 or 4 Lymphopenia in Patients Taking Cladribine Tablets 3.5mg/kg (P3.407)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Integrative molecular analysis of metastatic Merkel cell carcinoma to identify predictive biomarkers of response to avelumab

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9569-9569

2019

Volltextzugriff (PDF)

Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?

Journal of neuro-oncology, 2018-05, Vol.138 (1), p.163-171

2018

Volltextzugriff (PDF)

PO139 Integrated safety analysis; cladribine in multiple sclerosis (ms)

Journal of neurology, neurosurgery and psychiatry, 2017-12, Vol.88 (Suppl 1), p.A49-A49

2017

Volltextzugriff (PDF)

THUR 192 Yearly lymphopenia rates in cladribine tablets-treated rms patients

Journal of neurology, neurosurgery and psychiatry, 2018-10, Vol.89 (10), p.A27-A28

2018

Volltextzugriff (PDF)

Cladribine tablets in the treatment of patients with multiple sclerosis (MS): an integrated analysis of safety from the MS clinical development program (P5.394)

Neurology, 2017-04, Vol.88 (16_supplement)

2017

Volltextzugriff (PDF)

Effectiveness of Lymphocyte-based Re-treatment Criteria in Minimizing the Incidence of Severe Sustained Lymphopenia during Treatment with Cladribine Tablets 3.5mg/kg (P5.370)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(56)

Sprache

Englisch
(50)
Französisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer

Placebo influences on dyskinesia in Parkinson's disease

Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis

Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis

A phase I study of highly potent oral ATR inhibitor (ATRi) tuvusertib plus oral PARP inhibitor (PARPi) niraparib in patients with solid tumors

WED 182 Cladribine tablets effects on lymphocytes in ms patients

Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Long-term Lymphocyte Counts in Patients with RRMS Treated with Cladribine Tablets 3.5 mg/kg: Total Lymphocytes, B-, and T-cell Subsets (P5.364)

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study

First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors

PO135 Cladribine tablets in rrms: lymphocyte counts

Absolute lymphocyte count recovery in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY Extension (P5.379)

THUR 178 Infections during grade 3/4 lymphopenia with cladribine tablets

Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial

Integrated Safety Analysis of Infections during Periods of Grade 3 or 4 Lymphopenia in Patients Taking Cladribine Tablets 3.5mg/kg (P3.407)

Integrative molecular analysis of metastatic Merkel cell carcinoma to identify predictive biomarkers of response to avelumab

Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?

PO139 Integrated safety analysis; cladribine in multiple sclerosis (ms)

THUR 192 Yearly lymphopenia rates in cladribine tablets-treated rms patients

Cladribine tablets in the treatment of patients with multiple sclerosis (MS): an integrated analysis of safety from the MS clinical development program (P5.394)

Effectiveness of Lymphocyte-based Re-treatment Criteria in Minimizing the Incidence of Severe Sustained Lymphopenia during Treatment with Cladribine Tablets 3.5mg/kg (P5.370)

Suchergebnisse filtern